GlassScriptPhysician profile
James D Morris
NPI 1417026808
$11,285.75
in general payments reported to CMS, 2019-2025
34 companies · $935 in 2025
The $935 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $547 · 2021: $2,614 · 2022: $3,657 · 2023: $1,454 · 2024: $921 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,309.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $2,412.61 | 2022 | |
| Abbvie INC. | $2,229.20 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,076.16 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $853.38 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $790.44 | 2019-2025 | Stelara, Tremfya, Erleada |
| Pfizer INC. | $683.68 | 2019-2025 | |
| Erbe USA INC | $380.00 | 2019-2025 | Vio3, Erbe Vio3 |
| Gilead Sciences, INC. | $358.23 | 2020-2025 | Vemlidy, Epclusa |
| Celgene Corporation | $267.35 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $195.70 | 2019-2023 | Resolution 360 Ultra Clip |
| Daiichi Sankyo INC. | $183.86 | 2021-2023 | Injectafer |
| Janssen Scientific Affairs, LLC | $174.29 | 2022-2023 | Stelara |
| Dendreon Pharmaceuticals LLC | $142.07 | 2025 | Provenge |
| Genzyme Corporation | $54.06 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $50.26 | 2023 | Dupixent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $44.83 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $37.81 | 2023-2024 | Terlivaz |
| Ucb, INC. | $36.57 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $35.28 | 2025 | |
| Laborie Medical Technologies Corp. | $26.93 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $26.22 | 2019-2021 | |
| Dynavax Technologies Corporation | $24.14 | 2021 | |
| Progenics Pharmaceuticals, INC. | $23.30 | 2024 | |
| Blue Earth Diagnostics | $21.85 | 2025 | Posluma |
| Evoke Pharma, INC. | $20.72 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.24 | 2025 | Opsumit |
| Shire North American Group INC | $19.57 | 2019 | |
| Redhill Biopharma INC. | $18.53 | 2021 | |
| Ferring Pharmaceuticals INC. | $18.05 | 2024 | Adstiladrin |
| Neotract INC. | $16.21 | 2019 | |
| Qol Medical, LLC | $15.21 | 2019 | |
| Intercept Pharmaceuticals, INC. | $12.54 | 2020 | |
| Covidien LP | $12.22 | 2019 | |
| Veran Medical Technologies, INC. | $4.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.